UCB Reports Improved Results of Extended P-IIb BE ACTIVE study for Bimekizumab in Patients with Psoriatic Arthritis (PsA) Patients
Shots:
- The P-IIb study involves assessing of bimekizumab (160/320 mg@ 48 wks./16mg @12wks.- q4w SC IV) vs PBO in 206 patients in ratio (1:1) with PsA
- P-IIb BE ACTIVE study results: @12wks. ACR20/50/70/ (20%- 50% vs 7%-70%): PASI90/95 (90%-75%); @ 48wks. ACR20/50/70 (160- loading dose 160- 320): (70%- 73%- 76%; 55%- 57%- 63%; 43%- 46%- 39%); PASI90 (70%- 85%); MDA @12/24/48 wks. ((29-46%)- (37-60%)- (46-60%))
- Bimekizumab is a novel mIgG1 Ab neutralizes IL-17A and IL-17F. The above mentioned results are presented at ACR/ARHP18
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
